Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | SHBG | P04278 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8134135 | 0.92 | CYP1A2 (0.52) | CYP1A2MAPTSIGMAR1SHBG | |
| SCHEMBL7634653 | 0.87 | CYP1A2 (0.48) | CYP1A2SIGMAR1SHBGMETAP1 | |
| SCHEMBL8455180 | 0.86 | CYP1A2 (0.59) | CYP1A2MAPTSIGMAR1OPRK1METAP1 | |
| SCHEMBL20819147 | 0.86 | CYP1A2 (0.43) | CYP1A2MAPTSIGMAR1METAP1 | |
| SCHEMBL19189345 | 0.85 | CYP1A2 (0.44) | CYP1A2MAPTSIGMAR1SHBGMETAP1 | |
| SCHEMBL6933779 | 0.83 | CYP1A2 (0.50) | CYP1A2MAPTSIGMAR1OPRK1METAP1 | |
| Alcohol SCHEMBL17544758 | 0.82 | CYP1A2 (0.50) | CYP1A2MAPTSIGMAR1OPRK1METAP1 | |
| SCHEMBL28482634 | 0.82 | CYP1A2 (0.61) | CYP1A2MAPTSIGMAR1 | |
| SCHEMBL20272886 | 0.82 | CYP1A2 (0.39) | CYP1A2MAPTSIGMAR1 | |
| SCHEMBL2859393 | 0.82 | CYP1A2 (0.48) | CYP1A2MAPTSIGMAR1OPRK1METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | JAPAN TOBACCO INC. (JP) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054839-A1 | Method of inhibiting remnant lipoprotein production | CETP, PCSK9, LIPA | CYP1A2 1703/4885MAPT 4475/4885SIGMAR1 3364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.